The global Next Generation Sequencing Services Market is expected to grow at a CAGR of 19.9% from 2023 to 2030 to reach $20.39 billion by 2030. The growth of this market is mainly driven by the declining costs of sequencing procedures, the development & approval of new targeted therapies, the rising prevalence of cancer, partnerships between NGS service providers & pharmaceutical companies, the high cost of implementing sequencing infrastructure, and technological advancements in NGS. However, the availability of alternative technologies, the lack of skilled professionals for sample preparation & analysis, and the low chances of positive actionable mutations for precision medicine are factors restraining the growth of the NGS services market.
Furthermore, the increasing applications of NGS in cancer & agri-genomics research and advancements in sequencing data analytics are expected to generate market growth opportunities. However, regulatory & standardization concerns in diagnostic testing, the installation of in-house NGS facilities in large hospitals & research institutes, and the ethical issues & costs related to non-invasive prenatal genetic testing are major challenges for the stakeholders in this market.
Here are the top 10 companies operating in the Next Generation Sequencing Services Market
Illumina, Inc. (U.S.)
Incorporated in 1998 and headquartered in California, U.S., Illumina provides sequencing- and array-based solutions for genomic and genetic analysis. The company operates through two reportable segments: Core Illumina and GRAIL. The company offers NGS services through its Core Illumina segment. The company provides whole-genome sequencing, genotyping, noninvasive prenatal testing (NIPT), and product support services. The company provides human whole-genome sequencing services and NIPT services through its CLIA-certified, CAP-accredited laboratory.
Illumina provides its products and services to genomic research centers; academic institutions; government laboratories; hospitals; pharmaceutical, biotechnology, & commercial molecular diagnostics laboratories; and consumer genomics companies. The company has manufacturing sites and laboratories in the U.S., Singapore, and the U.K.
Illumina distributes its products globally in North America, Europe, Latin America, Asia-Pacific, and the Middle East & Africa through its distributors. Some of the subsidiaries operating in the NGS Services market are Illumina GmbH (Germany), Illumina Australia Pty. Ltd (Australia), Illumina UK, Ltd. (U.K.), Illumina Italy S.r.l. (Italy), Illumina Netherlands B.V. (Netherlands), and Illumina Japan K.K. Japan (Japan).
Eurofins Scientific S.E. (Luxembourg)
Founded in 1987 and headquartered in Luxembourg City, Luxembourg, Eurofins Scientific S.E. is a life science company that offers a range of analytical testing services across different industries. The company offers its products in five key areas: Clinical Diagnostics, Environmental Testing, Food and Feed Testing, Consumer Product Testing, and Bio-Pharmaceutical Services.
The company operates in the NGS Services market through the BioPharmaceutical Services and Clinical Diagnostics business area. Eurofins’ Next Generation Sequencing laboratories operate under Good Laboratory Practice (GLP) and ISO 17025 accreditations.
The company has a geographic presence in over 60 countries in Europe, North and South America, Asia-Pacific, the Middle East, and Africa. The company offers NGS services through its subsidiaries Diatherix (U.S.), Eurofins Viracor, Inc. (U.S.), and Eurofins BioPharma Product Testing Australia Pty Ltd. (Australia), among others.
Invitae Corporation (U.S.)
Founded in 2010 and headquartered in California, U.S., Invitae Corporation is a biotech company that provides genetic testing services, digital health solutions, and health data services for improved patient care and outcomes. The company offers genetic tests across various clinical areas, such as hereditary cancer, precision oncology, women’s health, rare diseases, and pharmacogenomics. The company operates in only one business segment.
The company’s key customers include patients, healthcare providers, payers, biopharma partners, and patient advocacy groups. The company has a geographic presence in the U.S., the U.K., Canada, Germany, India, Australia, Japan, the Netherlands, and Brazil, among others. Some of the subsidiaries of the company are ArcherDX, LLC (U.S.), ArcherDX Clinical Services, Inc. (U.S.), Genelex India Private Limited (India), Invitae Japan, KK (Japan), Invitae Netherlands, B.V. (Netherlands), and Invitae Australia PTY LTD (Australia), among others.
Foundation Medicine, Inc. (U.S.) (Subsidiary of F. Hoffmann-La Roche AG(Switzerland)
Founded in 2010 and headquartered in Massachusetts, U.S., Foundation Medicine, Inc. is a biotechnology company offering assays in next-generation sequencing, genomic profiling, and immunohistochemistry (IHC). The company provides its tests mainly for cancer diagnosis and treatment. The company offers three key assays: FoundationOneCDx, FoundationOne LiquidCDx, and FoundationOneHome, through which the company offers NGS test services. The FoundationOneCDx and FoundationOne LiquidCDx assays are approved by the U.S. FDA. As of 2021, the company profiled more than 500,000 patient samples and has more than 65 biopharma partners. The company is a subsidiary of F. Hoffmann-La Roche AG (Switzerland) and operates through its Pharmaceuticals Division.
Foundation Medicine has a presence in the U.S., Brazil, Romania, and Germany, among others. The company offers NGS services through its subsidiaries, such as Roche Products Pty Limited (Australia), Roche Products (India) Pvt. Ltd. (India), Roche Singapore Pte Ltd (Singapore), and Roche Korea Co. Ltd (Korea), among others.
Beijing Genomics Institute (China)
Established in 1999 and headquartered in Shenzhen, China, BGI provides proteomics and genomics sequencing services. The company provides various integrated genomic sequencing and proteomic solutions and services for pharmaceutical companies, medical institutions, healthcare providers, and other organizations.
The company provides its services to over 100 countries globally. As of 2021, the company has a headcount of 6,000 employees. The majority of the sequencing services of the company are done on the DNBSEQ NGS platform. In December 2019, the company offered free services of whole genome sequencing to support the researchers in the management of fall armyworm (sopdoptera frugiperda) species to protect the agricultural market globally. The company has offices in Demark, the U.S., China, and Japan.
Meticulous Research in its latest publication on Next Generation Sequencing Services Market has predicted the growth of 19.9% during the forecast year 2023-2030.
DirectLabs, LLC. (U.S.)
Founded in 1993 and headquartered in Los Angeles, U.S., DirectLabs, LLC. is engaged in offering direct access laboratory testing and a wide range of health and wellness blood chemistry tests. The company aims to assist in preventing and detecting early disease by providing its customers with affordable direct-to-consumer laboratory testing services.
Furthermore, it offers services all over the U.S. except in New Jersey, New York, and Rhode Island and direct-to-consumer laboratory testing at over 3000 locations across the U.S. The company also provides test results online within 24–48 hours. Its partner laboratories are CLIA-certified and regulated by appropriate governmental agencies.
Novogene Co., Ltd. (China)
Founded in 2011 and headquartered in Beijing, China, Novogene Co., Ltd. operates as a genomics solution provider and offers genomic solutions and services. The company has expertise in the area of NGS and services. Novogene Co., Ltd. has genomic sequencing labs in the U.S., China, Singapore, and the U.K. The UC Davis Sequencing Center, the U.S. subsidiary of the company, was opened in 2016; the subsidiary uses the Hi-Seq X Ten system to serve its customers within the country. The center provides NGS services and analyzes plant, human, and animal samples for research purposes. Novogene Co., Ltd. also established a College of American Pathologists (CAP) accredited medical lab in Tianjin (China).
The company provides services in the U.S., U.K., China, Japan, Netherlands, Singapore, and Thailand. NOVOGENE CO., LTD. Inc. (U.S.), Novogene (U.K.) Company Limited (U.K.), Novogene Netherlands B.V. (Netherlands), Novogene Japan K.K. (Japan), and Novogene N Health (Thailand) Company Limited (Thailand) are some of the subsidiaries of the company offering NGS Services.
PerkinElmer, Inc. (U.S.)
Founded in 1937 and headquartered in Massachusetts, U.S., PerkinElmer, Inc. is a multinational company that offers products, solutions, and services for the life sciences, diagnostics, and applied markets. It operates through two reportable business segments: Discovery & Analytical Solutions and Diagnostics. The company operates in the NGS Services market through the Diagnostics business segment. NGS services are offered through a global network of laboratories that offer testing in cytogenetics, biochemical genetics (prenatal and postnatal), molecular genetics, and immunodiagnostics. This laboratory network includes testing laboratories in the U.S., Sweden, India, China, and the U.K. In May 2023, PerkinElmer, Inc. rebranded its PerkinElmer Genomics section as Revvity Omics as the company’s genomics services business.
The company’s manufacturing and R&D facilities are located in several countries, including the U.S., China, Japan, and Germany. Furthermore, the company has a strong network of sales and marketing channels and service personnel in over 38 countries and sells its products and services in over 190 countries.
Macrogen, Inc. (South Korea)
Founded in 1997 and headquartered in Seoul, South Korea, Macrogen, Inc. is a biotechnology company that offers products in the area of precision medicine, next-generation sequencing (NGS), clinical diagnostics, microarray, oligo, gene synthesis, personal genome, and capillary electrophoresis sequencing (CES), among others. The company provides next-generation sequencing services such as the whole genome, de novo, exome, targeted, transcriptomics, metagenome, single-cell multi-omics sequencing, and epigenome sequencing.
Macrogen, Inc. provides genome research services in Korea and across the globe. The company has subsidiaries and branches in the U.S., Europe, Singapore, Japan, and Spain. Macrogen Japan Corp. (Japan), Psomagen, Inc. (U.S.), and Macrogen Asia Pacific Pte Ltd. (Singapore) are some of the subsidiaries of the company that operates in the NGS Services market.
QIAGEN N.V. (Netherlands)
Founded in 1984 and headquartered in Venlo, Netherlands, QIAGEN N.V. provides sample and assay technologies for molecular diagnostics, applied testing, and academic and pharmaceutical research. The company offers its products through only one reportable segment and provides them in two major markets: Molecular Diagnostics and Life Sciences.
The company offers a wide range of NGS services, such as RNA sequencing services, DNA sequencing services, whole genome amplification services, and RNA isolation services, among others, through its custom laboratory and genomic services. These NGS services offerings are offered under the Genomics/NGS products category.
The company markets products & services in more than 130 countries across the globe. The company has facilities located in the U.S., China, Germany, Poland, the Philippines, Denmark, Romania, Spain, the U.K., and other countries. The company’s expanded genomic service laboratories are located in Hilden, Germany, and Frederick, U.S.
GENEWIZ, Inc. (U.S.) (Subsidiary of Azenta, Inc. (U.S.))
Founded in 1999 and headquartered in New Jersey, U.S., GENEWIZ, Inc. provides R&D genomics services. The company offers services for next-generation sequencing, sanger sequencing, plasmid DNA preparation, PCR, gene synthesis, oligo synthesis, pre-clinical and clinical synthesis, and other services for pharma and biotech companies. The company offers its services in the research areas of cancer, infectious disease, biomarkers, agriculture, metagenomics, and antibody discovery, among others. GENEWIZ, Inc. offers standard and custom solutions for NGS library preparation, sequencing, extraction, and bioinformatics. The company mainly provides its products to academic institutions and pharma and biotech companies. GENEWIZ, Inc. is a subsidiary company of Azenta, Inc. (U.S.) (formerly Brooks Automation, Inc.). GENEWIZ. Inc. also provides raw sequence data with adjuvant quality scores, certificate of analysis, and signed QAU statement. GENEWIZ, Inc. has a geographic presence in the U.S., China, Germany, Japan, and the U.K.
Popular Mention: Quest Diagnostics Incorporated (U.S), LGC Limited (U.K.), DNA Link, Inc. (South Korea), SeqLL Inc. (U.S.).
Authoritative Research on the Next Generation Sequencing Services Market – Global Opportunity Analysis and Industry Forecast (2023-2030)
Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:
- Recent financial performance
- Key products
- Significant company strategies
- Partnerships and acquisitions
The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.